analogue du glp-1 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Analogues du GLP-1 versus inhibiteurs

Ozempic, already central in type 2 diabetes, has expanded with a new chronic kidney disease (CKD) label, reinforcing its role across the cardio-renal-metabolic spectrum. Wegovy Market Set to Expand as Obesity Treatment Demand Surges and GLP-1 Innovat The global Wegovy market is estimated to be valued at USD 10.96 Bn in 2025 and is expected to reach USD 31.51 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.3% from 2025 to 2032

Bottom line: MeAgain turns food logging into GLP-1 context

Appendix A Supplementary data to this article can be found online at Appendix A

If take-back options are unavailable, follow FDA guidelines for household disposal, which may include mixing with unpalatable substances and placing in sealed containers

Risks of gallbladder disease associated with GLP-1 medications